Telmisartan Effects on Insulin Resistance in Obese or Overweight Adults Without Diabetes or Hypertension
Authors:
Open Access
- 1 September 2010
- journal article
- research article
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 12 (9) , 746-752
Abstract
J Clin Hypertens (Greenwich). 2010;12:746–752. ©2010 Wiley Periodicals, Inc. Angiotensin receptor blockers (ARBs) are antihypertensive agents associated with reduced risk of new‐onset diabetes mellitus. The ARB telmisartan is a partial agonist of peroxisome proliferator–activated receptor‐gamma (PPAR‐γ). This study evaluated the effect of telmisartan on insulin resistance, a known target of PPAR‐γ agonism. Overweight/obese persons with body mass index ≥28 kg/m2, waist circumference ≥35 inches, and components of the metabolic syndrome without hypertension or diabetes who were not preselected for insulin resistance were enrolled. Patients were randomized to telmisartan or matching placebo for 16 weeks. The primary efficacy measure was changed from baseline in the insulin sensitivity index (SI), calculated from oral glucose tolerance testing. SI was also evaluated in a subset of patients using a hyperinsulinemic euglycemic clamp. Secondary end points included measures of insulin sensitivity and glucose and lipid metabolism. A total of 138 patients were randomized and received ≥1 dose of study medication; 128 completed the study. At end point, no significant difference was found between telmisartan and placebo groups regarding change from baseline in SI or in glucose area under the curve. No significant between‐group differences were found regarding glucose metabolism or lipoprotein levels. In the population with abdominal obesity and components of the metabolic syndrome, telmisartan did not increase insulin sensitivity.Keywords
This publication has 13 references indexed in Scilit:
- The angiotensin II receptor blocker telmisartan improves insulin resistance and has beneficial effects in hypertensive patients with type 2 diabetes and poor glycemic controlDiabetes Research and Clinical Practice, 2008
- Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular EventsNew England Journal of Medicine, 2008
- Renin-angiotensin system and cardiovascular riskThe Lancet, 2007
- The Impact of ACE Inhibitors or Angiotensin II Type 1 Receptor Blockers on the Development of New-Onset Type 2 DiabetesDiabetes Care, 2005
- Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndromeCardiovascular Diabetology, 2005
- Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activatorActa Diabetologica, 2005
- Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPARγ–Modulating ActivityHypertension, 2004
- Effects of Telmisartan Compared with Eprosartan on Blood Pressure Control, Glucose Metabolism and Lipid Profile in Hypertensive, Type 2 Diabetic Patients: a Randomized, Double-Blind, Placebo-Controlled 12-Month StudyHypertension Research, 2004
- Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololThe Lancet, 2002
- An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ)Journal of Biological Chemistry, 1995